Analysis identifies distinct cell profiles in BRAFV600E-negative gangliogliomas, suggesting new insights for epilepsy treatment.
Gangliogliomas are glioneuronal neoplasms, generally with a benign evolution, accounting for the most common tumors in patients with long-term pharmacoresistant epilepsy. BRAFV600E has been detected in a high percentage of World Health Organization grade 1 gangliogliomas. However, biopsy collections from epilepsy patients include tumors that meet neuropathological ganglioglioma criteria but lack the BRAFV600E mutation. The molecular pathology of such BRAFV600E-negative gangliogliomas remains largely unexplored. We here focused on decoding the molecular and cellular profiles of these BRAFV600E-negative gangliogliomas at the single-cell resolution. Our results identify an exclusive profile in excitatory, but not inhibitory, neurons, astrocytes and oligodendrocytes in BRAFV600E-negative gangliogliomas. Moreover, we confirm the presence of immature excitatory neurons with higher expression of genes related to glutamatergic transmission as well as metabolically active astro- and oligodendrocytes which may contribute to epileptogenicity. Our study provides important resources to understand the molecular profile of BRAFV600E-negative gangliogliomas aiming to drive forward future research directions to novel and tailored treatment options for epilepsy.
No takes yet. Share an insight, caveat, or question.
Cases‐Cunillera et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: